<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716713</url>
  </required_header>
  <id_info>
    <org_study_id>N8-2018-02</org_study_id>
    <nct_id>NCT03716713</nct_id>
  </id_info>
  <brief_title>CeraShield™ Endotracheal Tube Feasibility Study</brief_title>
  <official_title>CeraShield™ Endotracheal Tube Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>N8 Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>N8 Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, feasibility study to evaluate the Ceragenin Coated Endotracheal Tube (the
      CeraShield ETT) in adults who require intubation and are expected to be mechanically
      ventilated for ≥ 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 30 days post enrollment or hospital discharge, whichever comes first</time_frame>
    <description>The safety of the CeraShield ETT tube will be assessed by reviewing adverse events in all patients enrolled in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive QEA</measure>
    <time_frame>10 days post intubation</time_frame>
    <description>Determine the incidence of subjects with positive QEA in the patients intubated ≥ 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive ETT colonization</measure>
    <time_frame>10 days post intubation</time_frame>
    <description>Determine the incidence of subjects with ETT colonization in the patients intubated ≥ 24 hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Intubation, Intratracheal</condition>
  <arm_group>
    <arm_group_label>CeraShield Endotracheal Tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CeraShield Endotracheal Tube</intervention_name>
    <description>Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT</description>
    <arm_group_label>CeraShield Endotracheal Tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 years or older;

          -  Patients requiring a 7.0mm, 7.5mm, 8.0mm or 8.5mm endotracheal tube;

          -  Expected to be mechanically ventilated for ≥24 hours.

        Exclusion Criteria:

          -  Currently participating in another clinical trial which conflicts with this trial's
             design.

          -  Patients with a pre-existing respiratory infection, i.e., pneumonia.

          -  Patients with pulmonary contusions.

          -  Patients with cystic fibrosis.

          -  Patients demonstrating symptoms of bronchiectasis.

          -  Patients demonstrating symptoms of severe or massive hemoptysis. Severe or massive
             hemoptysis defined as greater than 500 ml of blood per day, or greater than 200 ml in
             six hours.

          -  Patients who have been intubated within the last 30 days requiring reintubation.

          -  Women of child-bearing potential who have not undergone a pregnancy test will be
             excluded from the study.

          -  Patient is pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jane Wilson</last_name>
    <phone>845-721-8210</phone>
    <email>janew@databean.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Hunt</last_name>
      <phone>613 549 6666</phone>
      <phone_ext>3190</phone_ext>
      <email>miranda.hunt@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Boyd</last_name>
      <phone>613 549 6666</phone>
      <phone_ext>2608</phone_ext>
      <email>tracy.boyd@kingstonhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>John Muscedere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

